Medivir Q3 2022: fostrox’s dose escalation is nearing completion - Redeye

Redeye comments on Medivir's third quarter report. There have been some positive developments in fostrox's ongoing clinical trial in liver cancer, and the full results from the LEAP-02 trial, which studied lenvatinib + pembrolizumab, have now been published.

Länk till analysen i sin helhet: https://www.redeye.se/research/861291/medivir-q3-2022-fostroxs-dose-escalation-is-nearing-completion?utm_source=finwire&utm_medium=RSS